Treatment of er+ breast cancer comprising homologous recombination deficiency using parg inhibitor
AssigneeIdeaya Biosciences, Inc.
InventorsMonah ABED, Diana Marcela MUNOZ DELGADO, Mark LACKNER, Zineb MOUNIR, Vidya SESHADRI
Life of this patent
Estimating the term…
Abstract
The present disclosure concerns new methods of treating cancer, e.g., breast cancer, in a patient in need thereof, comprising, inter alia, the use of poly(ADP-ribose) glycohydrolase (PARG) modulators, or pharmaceutically acceptable salts thereof.
Claims53
A Poly(ADP-ribose) glycohydrolase (PARG) modulator for use in a method of treating breast cancer in a patient in need thereof, wherein the patient has a breast cancer tumor and the tumor comprises homologous recombination deficiency (HRD) and is estrogen receptor (ER) positive (ER+), the method comprising administering a therapeutically effective amount of the PARG modulator to the patient in need thereof.
A method of treating breast cancer in a patient in need thereof, the method comprising:
- (a) selecting a patient having a breast cancer tumor wherein the tumor comprises homologous recombination deficiency (HRD) and is estrogen receptor (ER) positive (ER+);
- and
- (b) administering to the patient in need thereof, a therapeutically effective amount of a Poly(ADP-ribose) glycohydrolase (PARG) modulator.
Use of a Poly(ADP-ribose) glycohydrolase (PARG) modulator in the manufacture of a medicament for treating breast cancer in a patient in need thereof, wherein the breast cancer in the patient is a tumor and the tumor comprises homologous recombination deficiency (HRD) and is estrogen receptor (ER) positive (ER+).
A method of identifying a breast cancer patient susceptible to treatment with a Poly(ADP-ribose) glycohydrolase (PARG) modulator, the method comprising:
- (a) identifying a patient having a breast cancer tumor, and
- (b) obtaining information about a biological sample of the breast cancer tumor and evaluating the information about the biological sample to determine whether the breast cancer tumor comprises homologous recombination deficiency (HRD) and is estrogen receptor (ER) positive (ER+).
Dependencies are inferred from the claim text.